Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Experts debate optimal 25-hydroxyvitamin D (25[OH]D) levels for musculoskeletal health.

Who Took Part

According to the abstract, 230 women were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some women received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

This randomized, double-blind, placebo-controlled clinical trial was conducted at a single center in Madison, Wisconsin, from May 1, 2010, through July 31, 2013, and the final visit was completed on August 8, 2014.

What Was Measured

Experts debate optimal 25-hydroxyvitamin D (25[OH]D) levels for musculoskeletal health.

Topics PubMed links to this paper include Absorptiometry, Photon, Bone Density, Bone Density Conservation Agents, Calcium Radioisotopes, Cholecalciferol, Drug Monitoring and Motor Activity.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 230 women.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (JAMA internal medicine), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.